top of page

The Potential Role of Amyloid Beta Peptides Concussion Biomarkers Reported



Increased levels of circulating amyloid beta (abeta) - 40 and -42 peptides are often increased after concussion. As such, these peptides are promising blood biomarkers of post-concussive events and neurological damage. Concussion-like symptoms are also associated with increased abeta in peripheral blood after blast exposure devoid of a clinically defined injury. A recently published review and opinion article highlights recent work describing abeta elevation in peripheral blood among persons with probable or diagnosed concussion. The authors propose utility of abeta to augment clinical examination or provide rationale for continuous, post-event monitoring.


These studies were originally featured in

Frontiers Neurology, Neurotrauma - Insights in Neurotrauma: 2021


“Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion”


Angela M Boutté, Ph.D., Bharani Thangavelu, Ph.D., and John Anagli, Ph.D.




Aries Biotech is a neurological disease and dementia biomarker consulting company.


To learn how we can augment your needs, visit Aries Biotech at https://www.ariesbiotechnologies.org

20 views0 comments

Recent Posts

See All

Thank you - Alzheimer’s Research UK!

Aries Biotech extends gratitude to the Alzheimer’s Research UK team, for inviting Dr. Angela Boutte, the founder of Aries Biotech, as a...

Comments


Golden Gate Bridge

Contact Us

Thank you. Aries Biotech will respond shortly.

Aries Biotech Consulting
4440 Keller Avenue, Suite 140, Box 199, Oakland, CA 94605
E-mail:  ariesbiotech.consult@gmail.com
Office
/Msg Ph:  650-246-9476

 

Subscribe for News and Updates

Thanks for submitting!

Disclaimer - This site and services are solely affiliated with Aries Biotech.
Name and logo are protected by trademark (USPTO No. 5826  and No. 5827).

bottom of page